Intel employee who advocated for having his prostate tumor sequenced at OHSU, "which had one of the earliest capabilities for such sequencing," is profiled in Forbes magazine.

OHSU's Long COVID-19 program is mentioned in a story picked up by radio stations around the country about Long COVID-19 patients who experience relief from symptoms after being vaccinated.

The OHSU School of Medicine's primary care program ranks among the the nation's top 5, according to U.S. News & World Report's Best Graduate Schools.

Former U.S. Attorney General Eric Holder of Covington & Burling LLC will lead a comprehensive, independent investigation of institutional harassment, discrimination, retaliation and racism at OHSU.

Press release reporting year-end financial results for Seer, Inc. references pilot studies underway at the OHSU Knight Cancer Institute and the Broad Institute.

OHSU is among hospitals and clinics in Oregon to participate as an Age-Friendly Health System recognized by the John A. Hartford Foundation.

OHSU partnered with Multnomah County’s Racial and Ethnic Approaches to Community Health program to organize a community vaccine clinic at Emmanuel Temple Church in Portland March 28-29 to improve vaccine access for local communities of color. Donn Spight, M.D., said: “Many different groups of color have been disproportionately impacted by COVID and find themselves limited by structural barriers to access and oftentimes concern about the safety and efficacy of the vaccine.”

While describing OHSU’s new Long COVID-19 Program for patients who have experienced coronavirus symptoms for more than a month, Eric Herman, M.D., says: "There are still many questions we're looking for answers to. Despite that I think that we can offer many things to patients to accelerate their healing and get better."

A year since the onset of the pandemic, story highlights laboratories at OHSU, the University of Oregon and Oregon State University studying virus mutations.

Studies published in Science and Science Immunology and led by Louis Picker, M.D., and Klaus Frueh, Ph.D., describe the biological mechanisms that make OHSU’s cytomegalovirus-based vaccine candidate effective at stopping and clearing HIV.